An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
NCT00057213 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 367
Last updated 2015-04-16
Summary
A Placebo Controlled Study Evaluating Efficacy, Safety and Tolerability of Medication in Patients with Major Depressive Disorder (MDD)
Conditions
- Depressive Disorder, Major
Interventions
- DRUG
-
Radafaxine
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
GSK Clinical Trials · GlaxoSmithKline
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 64 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2003-03-31
- Primary Completion
- 2007-04-30
- Completion
- 2007-04-30
Countries
- United States
Study Locations
More Related Trials
-
Efficacy Study of RX-10100 to Treat Major Depressive Disorder (MDD)
NCT00839176 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of RX-10100 to Treat Major Depressive Disorder
NCT01273376 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of RO4917523 in Patients With Treatment Resistant Depression
NCT00809562 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of GW856553X For the Treatment of Depression
NCT00569062 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of JNJ-61393215 in the Treatment of Depression
NCT04080752 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
NCT01309945 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine
NCT06280235 ·Status: COMPLETED ·Phase: PHASE2
-
Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo
NCT04221230 ·Status: COMPLETED ·Phase: PHASE2
-
A Placebo-Controlled Study to Investigate the Onset of Action of Paroxetine in Premenstrual Dysphoria
NCT00516113 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)
NCT02932943 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Desvenlafaxine in Treating Major Depressive Disorder.
NCT04364997 ·Status: COMPLETED ·Phase: PHASE3
-
MDD POC Study GSK372475 Subjects Depressive Disease
NCT00420641 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression
NCT03559192 ·Status: COMPLETED ·Phase: PHASE2
-
Duloxetine Compared to Escitalopram and Placebo in the Treatment of Patients With Depression
NCT00073411 ·Status: COMPLETED ·Phase: PHASE3
-
A Safety, Efficacy and Tolerability Study of SEP-225289
NCT00584974 ·Status: COMPLETED ·Phase: PHASE2
-
An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress
NCT02498392 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Rapastinel as Monotherapy in Patients With MDD
NCT03560518 ·Status: TERMINATED ·Phase: PHASE3
-
A Trial of AXS-05 in Patients With Major Depressive Disorder
NCT04019704 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)
NCT03614156 ·Status: TERMINATED ·Phase: PHASE3
-
Open-Label Treatment With Duloxetine Hydrochloride Once-Daily Dosing for Evaluation of Stabilization Dose in Patients With Major Depression
NCT00042562 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
NCT06029426 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)
NCT02943564 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder
NCT05376150 ·Status: COMPLETED ·Phase: PHASE2
-
Zelquistinel in the Treatment of Major Depressive Disorder
NCT03586427 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate Efficacy and Safety of GW117 Tablets in Major Depressive Disorder
NCT06796868 ·Status: COMPLETED ·Phase: PHASE2